South Korea · Delayed Price · Currency is KRW Revance Therapeutics Statistics
Total Valuation
High Tech Pharm has a market cap or net worth of KRW 133.77 billion. The enterprise value is 126.17 billion.
| Market Cap | 133.77B |
| Enterprise Value | 126.17B |
Important Dates
The next estimated earnings date is Wednesday, August 13, 2025.
| Earnings Date | Aug 13, 2025 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
High Tech Pharm has 10.63 million shares outstanding.
| Current Share Class | 10.63M |
| Shares Outstanding | 10.63M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 5.54% |
| Owned by Institutions (%) | 0.30% |
| Float | 5.84M |
Valuation Ratios
The trailing PE ratio is 10.59.
| PE Ratio | 10.59 |
| Forward PE | n/a |
| PS Ratio | 1.82 |
| PB Ratio | 1.11 |
| P/TBV Ratio | 1.11 |
| P/FCF Ratio | 13.52 |
| P/OCF Ratio | 11.27 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.45, with an EV/FCF ratio of 12.75.
| EV / Earnings | 9.99 |
| EV / Sales | 1.71 |
| EV / EBITDA | 6.45 |
| EV / EBIT | 8.80 |
| EV / FCF | 12.75 |
Financial Position
The company has a current ratio of 3.60, with a Debt / Equity ratio of 0.07.
| Current Ratio | 3.60 |
| Quick Ratio | 1.63 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | 0.41 |
| Debt / FCF | 0.81 |
| Interest Coverage | 21.74 |
Financial Efficiency
Return on equity (ROE) is 10.96% and return on invested capital (ROIC) is 7.03%.
| Return on Equity (ROE) | 10.96% |
| Return on Assets (ROA) | 6.22% |
| Return on Invested Capital (ROIC) | 7.03% |
| Return on Capital Employed (ROCE) | 11.71% |
| Revenue Per Employee | 1.13B |
| Profits Per Employee | 194.26M |
| Employee Count | 65 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 1.57 |
Taxes
In the past 12 months, High Tech Pharm has paid 2.91 billion in taxes.
| Income Tax | 2.91B |
| Effective Tax Rate | 18.75% |
Stock Price Statistics
The stock price has decreased by -22.82% in the last 52 weeks. The beta is 0.80, so High Tech Pharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.80 |
| 52-Week Price Change | -22.82% |
| 50-Day Moving Average | 12,875.20 |
| 200-Day Moving Average | 13,985.60 |
| Relative Strength Index (RSI) | 44.09 |
| Average Volume (20 Days) | 18,163 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, High Tech Pharm had revenue of KRW 73.58 billion and earned 12.63 billion in profits. Earnings per share was 1,187.54.
| Revenue | 73.58B |
| Gross Profit | 18.31B |
| Operating Income | 14.34B |
| Pretax Income | 15.54B |
| Net Income | 12.63B |
| EBITDA | 19.56B |
| EBIT | 14.34B |
| Earnings Per Share (EPS) | 1,187.54 |
Balance Sheet
The company has 15.58 billion in cash and 7.99 billion in debt, giving a net cash position of 7.59 billion or 714.16 per share.
| Cash & Cash Equivalents | 15.58B |
| Total Debt | 7.99B |
| Net Cash | 7.59B |
| Net Cash Per Share | 714.16 |
| Equity (Book Value) | 120.86B |
| Book Value Per Share | 11,366.85 |
| Working Capital | 48.58B |
Cash Flow
In the last 12 months, operating cash flow was 11.87 billion and capital expenditures -1.98 billion, giving a free cash flow of 9.90 billion.
| Operating Cash Flow | 11.87B |
| Capital Expenditures | -1.98B |
| Free Cash Flow | 9.90B |
| FCF Per Share | 930.75 |
Margins
Gross margin is 24.88%, with operating and profit margins of 19.49% and 17.16%.
| Gross Margin | 24.88% |
| Operating Margin | 19.49% |
| Pretax Margin | 21.12% |
| Profit Margin | 17.16% |
| EBITDA Margin | 26.59% |
| EBIT Margin | 19.49% |
| FCF Margin | 13.45% |
Dividends & Yields
This stock pays an annual dividend of 100.00, which amounts to a dividend yield of 0.79%.
| Dividend Per Share | 100.00 |
| Dividend Yield | 0.79% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 5.61% |
| Buyback Yield | n/a |
| Shareholder Yield | 0.79% |
| Earnings Yield | 9.44% |
| FCF Yield | 7.40% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on December 27, 2023. It was a forward split with a ratio of 1.5.
| Last Split Date | Dec 27, 2023 |
| Split Type | Forward |
| Split Ratio | 1.5 |
Scores
High Tech Pharm has an Altman Z-Score of 6.78 and a Piotroski F-Score of 5.
| Altman Z-Score | 6.78 |
| Piotroski F-Score | 5 |